Multigene Panel Testing in a Large Cohort of Adults With Epilepsy

In the Research Article “Multigene Panel Testing in a Large Cohort of Adults With Epilepsy: Diagnostic Yield and Clinically Actionable Genetic Findings” by McKnight et al.,¹ the pie chart in Figure 4A should illustrate that molecular diagnoses were associated with surgical indications in 27 individuals and with surgical contraindications in 37 individuals. A corrected Figure 4 is below. Additionally, the third sentence under Clinically Actionable Findings in the Results section should read as follows: “Diagnostic findings in genes with ASM indications were the most common category of clinically actionable findings (n = 98), followed by those in genes with possible surgical interventions (n = 64) (Figure 4A).” The authors regret the errors.

Figure 4. Clinically Actionable Genetic Findings, Overall and Among Individuals With Pharmacoresistant Seizures.

(A) All definitive molecular diagnoses and (B) definitive molecular diagnoses with pharmacoresistant seizures were categorized according to whether the diagnostic finding was in a gene with a published clinical action and if so, the type (ASM indications, ASM contraindications, metabolic treatments, possible surgical indications, or surgical contraindications). Individuals with clinically actionable findings in more than 1 category were counted more than once. A full list of clinically actionable genetic findings can be found in eTable 3 (links.lww.com/NXG/A505). ASM = antiseizure medication.